MorphoSys
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, MorphoSys sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
MorphoSys: 7 sponsored US clinical trials, none currently recruiting.
MorphoSys sponsors 7 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 6 completed. 0 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Leukemia, Lymphocytic, Chronic, B-Cell, with 1 trials.
Upper-quartile sponsor footprint
MorphoSys sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
7 total, page 1 of 1
Observational Retrospective Cohort Study of Systemic Therapies for R/R DLBCL
NCT04697160
Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL
NCT04134936
Lenalidomide Monotherapy in R/R DLBCL
NCT04150328
Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi
NCT02639910
Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL
NCT02399085
Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL)
NCT01685008
Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)
NCT01685021
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 4 |
Therapeutic Areas
How the MorphoSys early-phase archive is shaped
7 indexed studies, none listed as recruiting (0% open); 6 completed (86%).
Phase mix: 0 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: Leukemia, Lymphocytic, Chronic, B-Cell (1 trial), 3 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
MorphoSys: archived-pipeline peers nationwide
Peers matched on 7 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
MorphoSys sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 archived trials
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this MorphoSys page
7 registered trials is a research-attention snapshot, not an endorsement of MorphoSys or any single study.
- None of MorphoSys's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Leukemia, Lymphocytic, Chronic, B-Cell is the condition MorphoSys studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Leukemia, Lymphocytic, Chronic, B-Cell trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
MorphoSys pipeline card: 7 registered trials from official public datasets.Report a data error.